Identification and functional analysis of the SARS-COV-2 nucleocapsid protein

A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analys...

Full description

Saved in:
Bibliographic Details
Published inBMC microbiology Vol. 21; no. 1; pp. 58 - 10
Main Authors Gao, Tianyi, Gao, Yingdong, Liu, Xiangxiang, Nie, Zhenlin, Sun, Huilin, Lin, Kang, Peng, Hongxin, Wang, Shukui
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.02.2021
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets. The SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN. SARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function. In this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine.
AbstractList A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets.BACKGROUNDA severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets.The SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN.METHODSThe SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN.SARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function.RESULTSSARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function.In this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine.CONCLUSIONIn this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine.
A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets. The SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN. SARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function. In this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine.
Abstract Background A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets. Methods The SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN. Results SARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function. Conclusion In this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine.
Background A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets. Methods The SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN. Results SARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function. Conclusion In this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine.
A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets. The SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN. SARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function. In this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine.
Background A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets. Methods The SARS-COV-2 N protein subcellular localization and physicochemical property was analyzed by PSORT II Prediction and ProtParam tool. Then SOPMA tool and swiss-model was applied to analyze the structure of N protein. Next, the biological function was explored by mass spectrometry analysis and flow cytometry. At last, its potential phosphorylation sites were analyzed by NetPhos3.1 Server and PROVEAN PROTEIN. Results SARS-COV-2 N protein composed of 419 aa, is a 45.6 kDa positively charged unstable hydrophobic protein. It has 91 and 49% similarity to SARS-CoV and MERS-CoV and is predicted to be predominantly a nuclear protein. It mainly contains random coil (55.13%) of which the tertiary structure was further determined with high reliability (95.76%). Cells transfected with SARS-COV-2 N protein usually show a G1/S phase block company with an increased expression of TUBA1C, TUBB6. At last, our analysis of SARS-COV-2 N protein predicted a total number of 12 phosphorylated sites and 9 potential protein kinases which would significantly affect SARS-COV-2 N protein function. Conclusion In this study, we report the physicochemical properties, subcellular localization, and biological function of SARS-COV-2 N protein. The 12 phosphorylated sites and 9 potential protein kinase sites in SARS-COV-2 N protein may serve as promising targets for drug discovery and development for of a recombinant virus vaccine. Keywords: SARS-COV-2, Nucleocapsid protein (N protein), Structure, Phosphorylation
ArticleNumber 58
Audience Academic
Author Peng, Hongxin
Lin, Kang
Gao, Yingdong
Liu, Xiangxiang
Nie, Zhenlin
Sun, Huilin
Wang, Shukui
Gao, Tianyi
Author_xml – sequence: 1
  givenname: Tianyi
  surname: Gao
  fullname: Gao, Tianyi
– sequence: 2
  givenname: Yingdong
  surname: Gao
  fullname: Gao, Yingdong
– sequence: 3
  givenname: Xiangxiang
  surname: Liu
  fullname: Liu, Xiangxiang
– sequence: 4
  givenname: Zhenlin
  surname: Nie
  fullname: Nie, Zhenlin
– sequence: 5
  givenname: Huilin
  surname: Sun
  fullname: Sun, Huilin
– sequence: 6
  givenname: Kang
  surname: Lin
  fullname: Lin, Kang
– sequence: 7
  givenname: Hongxin
  surname: Peng
  fullname: Peng, Hongxin
– sequence: 8
  givenname: Shukui
  surname: Wang
  fullname: Wang, Shukui
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33618668$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1v0zAUhi00xD7gD3CBInEDFxn-SGznBqmqGFQamrQCt5ZjH3euUrvECWL_fk67wTohFEWxnec8OTl6T9FRiAEQek3wOSGSf0iESs5LTMl0Y1GyZ-iEVIKUlEh89Gh9jE5TWmNMhGTiBTpmjGcBlyfo68JCGLzzRg8-hkIHW7gxmGmju7zV3W3yqYiuGG6gWM6ul-X86kdJizCaDqLR2-Rtse3jAD68RM-d7hK8un-eoe8Xn77Nv5SXV58X89llaepGDKWUNeG1lpxqJivm2spioM4IUoFsueG1MABEN6wF13DHHAOMrWjrlnHAnJ2hxd5ro16rbe83ur9VUXu1O4j9Sul-8LlBJR0XVV012EhWaTANNaTi1FJpLLZUZNfHvWs7thuwJo-j192B9PBN8DdqFX8pIRuJ6dTMu3tBH3-OkAa18clA1-kAcUyKVg3ltZRUZvTtE3Qdxz7POFN1dhGKGftLrXT-AR9czN81k1TNeM14TSmdqPN_UPmysPEmJ8X5fH5Q8P6gIDMD_B5WekxJLZbXh-ybx0P5M42H4GRA7gHTx5R6cMr4YReh3IXvFMFqyqjaZ1TlfKpdRtXkpk9KH-z_KboDTOHlFQ
CitedBy_id crossref_primary_10_3390_v14112499
crossref_primary_10_2174_0929867329666221004104430
crossref_primary_10_3389_fpubh_2024_1386596
crossref_primary_10_1016_j_jsb_2022_107879
crossref_primary_10_1093_ofid_ofae561
crossref_primary_10_1016_j_imu_2022_100889
crossref_primary_10_1016_j_smaim_2023_12_003
crossref_primary_10_1080_13880209_2022_2039215
crossref_primary_10_3390_vaccines9111337
crossref_primary_10_7759_cureus_48637
crossref_primary_10_3390_ijms24119589
crossref_primary_10_3390_bios14110514
crossref_primary_10_1186_s12916_025_03971_w
crossref_primary_10_1002_adfm_202405340
crossref_primary_10_3390_s24227382
crossref_primary_10_4103_mjdrdypu_mjdrdypu_819_22
crossref_primary_10_1080_07391102_2022_2162131
crossref_primary_10_1186_s12964_023_01104_5
crossref_primary_10_1186_s12964_024_01818_0
crossref_primary_10_3390_toxins14100683
crossref_primary_10_1089_vim_2022_0059
crossref_primary_10_1016_j_omtn_2023_02_010
crossref_primary_10_1128_spectrum_03410_23
crossref_primary_10_3390_v16050757
crossref_primary_10_3390_ijms23116083
crossref_primary_10_1080_07391102_2021_1996463
crossref_primary_10_1007_s00216_024_05174_3
crossref_primary_10_3390_v14091966
crossref_primary_10_3390_ijms23148006
crossref_primary_10_1038_s41598_022_22658_3
crossref_primary_10_1080_07391102_2021_1958061
crossref_primary_10_1016_j_ijbiomac_2022_01_094
crossref_primary_10_1099_jgv_0_001918
crossref_primary_10_3389_fmicb_2022_851202
crossref_primary_10_1186_s44149_024_00118_x
crossref_primary_10_3390_diagnostics11122346
crossref_primary_10_1371_journal_pone_0270717
crossref_primary_10_18633_biotecnia_v27_2485
crossref_primary_10_1134_S1068162023050229
crossref_primary_10_3389_fimmu_2023_1254128
crossref_primary_10_52396_JUSTC_2022_0020
crossref_primary_10_3389_fmats_2022_1059184
crossref_primary_10_3390_v15051085
crossref_primary_10_3389_fgene_2022_984068
crossref_primary_10_1155_2021_8853056
crossref_primary_10_22159_ajpcr_2023_v16i10_48095
crossref_primary_10_1007_s10142_023_01079_z
crossref_primary_10_1007_s10528_025_11041_2
crossref_primary_10_1016_j_ymthe_2022_12_002
crossref_primary_10_3390_app15020786
crossref_primary_10_1016_j_pep_2023_106263
crossref_primary_10_1186_s12864_024_10372_5
crossref_primary_10_1038_s41392_022_01048_1
crossref_primary_10_1038_s41423_021_00752_2
crossref_primary_10_3389_fcimb_2022_1040248
crossref_primary_10_3389_fmed_2022_815389
crossref_primary_10_3390_v15061394
crossref_primary_10_3389_fimmu_2022_984553
crossref_primary_10_1016_j_psj_2024_104240
crossref_primary_10_1109_JSEN_2022_3181580
crossref_primary_10_3390_vaccines11121810
crossref_primary_10_1007_s10562_025_04974_1
crossref_primary_10_1051_bioconf_20237502005
crossref_primary_10_31857_S0132342323050081
Cites_doi 10.1016/j.jviromet.2019.113806
10.1002/pmic.200300771
10.1128/JVI.00773-17
10.1038/s41579-018-0118-9
10.1006/jmbi.1996.0628
10.3389/fonc.2020.00049
10.1186/1476-069X-2-15
10.1093/nar/gky427
10.1016/j.antiviral.2014.12.011
10.1016/j.tcb.2018.08.003
10.1093/bioinformatics/btv195
10.1016/j.antiviral.2013.12.009
10.1016/j.csbj.2020.08.006
10.1128/JVI.00948-15
10.1128/JVI.03300-13
10.3390/v6082991
10.1038/nrm2609
10.4161/cc.6.7.4032
10.1093/gbe/evu187
10.1007/s00203-020-01998-6
10.1128/JVI.03017-13
10.1016/S0968-0004(99)01540-6
10.1093/nar/gkg563
10.1093/nar/gkw1132
10.1101/2020.01.24.919183
10.1128/JVI.01925-19
10.1101/2020.01.23.20018549
10.1101/2020.01.28.922922
10.1002/jmv.25681
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2021
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
– notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7QL
7T7
7U9
7X7
7XB
88E
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7N
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12866-021-02107-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
PML(ProQuest Medical Library)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



Publicly Available Content Database
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1471-2180
EndPage 10
ExternalDocumentID oai_doaj_org_article_8f6745490c834aec92c1462d28cd0d27
PMC7898026
A653652223
33618668
10_1186_s12866_021_02107_3
Genre Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
7X7
88E
8FE
8FH
8FI
8FJ
A8Z
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ISR
ITC
KQ8
LK5
LK8
M1P
M48
M7P
M7R
MM.
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~02
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
PMFND
3V.
7QL
7T7
7U9
7XB
8FD
8FK
AZQEC
C1K
COVID
DWQXO
FR3
GNUQQ
H94
K9.
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c597t-885165a862a3843fb4d0e2fc714e8b6c657cee1a93bef96f3f3e00d7b5b36e063
IEDL.DBID M48
ISSN 1471-2180
IngestDate Wed Aug 27 01:32:43 EDT 2025
Thu Aug 21 14:12:51 EDT 2025
Fri Jul 11 06:07:37 EDT 2025
Fri Jul 25 09:13:16 EDT 2025
Tue Jun 17 21:27:18 EDT 2025
Tue Jun 10 20:37:23 EDT 2025
Fri Jun 27 04:19:24 EDT 2025
Mon Jul 21 05:52:28 EDT 2025
Tue Jul 01 04:31:35 EDT 2025
Thu Apr 24 23:04:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Phosphorylation
Structure
SARS-COV-2
Nucleocapsid protein (N protein)
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c597t-885165a862a3843fb4d0e2fc714e8b6c657cee1a93bef96f3f3e00d7b5b36e063
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12866-021-02107-3
PMID 33618668
PQID 2502612033
PQPubID 42585
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_8f6745490c834aec92c1462d28cd0d27
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7898026
proquest_miscellaneous_2492658828
proquest_journals_2502612033
gale_infotracmisc_A653652223
gale_infotracacademiconefile_A653652223
gale_incontextgauss_ISR_A653652223
pubmed_primary_33618668
crossref_citationtrail_10_1186_s12866_021_02107_3
crossref_primary_10_1186_s12866_021_02107_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-02-22
PublicationDateYYYYMMDD 2021-02-22
PublicationDate_xml – month: 02
  year: 2021
  text: 2021-02-22
  day: 22
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC microbiology
PublicationTitleAlternate BMC Microbiol
PublicationYear 2021
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References A Khan (2107_CR8) 2020; 18
CK Chang (2107_CR10) 2014; 103
R Cawood (2107_CR15) 2007; 6
J Pontius (2107_CR31) 1996; 264
G Zhu (2107_CR7) 2020; 1
2107_CR5
S Bienert (2107_CR30) 2017; 45
2107_CR3
2107_CR2
2107_CR1
J Nieuwenhuis (2107_CR18) 2019; 29
Y Chen (2107_CR9) 2020; 92
Y Cong (2107_CR12) 2020; 94
A Sheikh (2107_CR25) 2020; 277
R McBride (2107_CR13) 2014; 6
C Combet (2107_CR28) 2000; 25
N Blom (2107_CR32) 2004; 4
Y Wang (2107_CR22) 2015; 89
KW Cheng (2107_CR21) 2015; 115
D Ross-Thriepland (2107_CR24) 2014; 88
MAH Albahde (2107_CR19) 2020; 10
E Gasteiger (2107_CR27) 2003; 31
P Findeisen (2107_CR20) 2014; 6
M Glotzer (2107_CR17) 2009; 10
Y Cui (2107_CR4) 2003; 2
T Goto (2107_CR16) 2017; 91
Y Choi (2107_CR33) 2015; 31
A Kato (2107_CR23) 2014; 88
A Waterhouse (2107_CR29) 2018; 46
J Cui (2107_CR6) 2019; 17
2107_CR14
2107_CR11
Y Yuan (2107_CR26) 2017; 8
References_xml – volume: 277
  start-page: 113806
  year: 2020
  ident: 2107_CR25
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2019.113806
– volume: 4
  start-page: 1633
  issue: 6
  year: 2004
  ident: 2107_CR32
  publication-title: Proteomics.
  doi: 10.1002/pmic.200300771
– volume: 91
  start-page: e00773
  issue: 22
  year: 2017
  ident: 2107_CR16
  publication-title: J Virol
  doi: 10.1128/JVI.00773-17
– volume: 17
  start-page: 181
  issue: 3
  year: 2019
  ident: 2107_CR6
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-018-0118-9
– volume: 264
  start-page: 121
  issue: 1
  year: 1996
  ident: 2107_CR31
  publication-title: J Mol Biol
  doi: 10.1006/jmbi.1996.0628
– volume: 10
  start-page: 49
  year: 2020
  ident: 2107_CR19
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.00049
– volume: 2
  start-page: 15
  issue: 1
  year: 2003
  ident: 2107_CR4
  publication-title: Environ Health
  doi: 10.1186/1476-069X-2-15
– volume: 46
  start-page: W296
  issue: W1
  year: 2018
  ident: 2107_CR29
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky427
– volume: 115
  start-page: 9
  year: 2015
  ident: 2107_CR21
  publication-title: Antivir Res
  doi: 10.1016/j.antiviral.2014.12.011
– volume: 29
  start-page: 80
  issue: 1
  year: 2019
  ident: 2107_CR18
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2018.08.003
– volume: 1
  start-page: 53
  year: 2020
  ident: 2107_CR7
  publication-title: Curr Res Microb Sci
– volume: 31
  start-page: 2745
  issue: 16
  year: 2015
  ident: 2107_CR33
  publication-title: Bioinformatics.
  doi: 10.1093/bioinformatics/btv195
– ident: 2107_CR2
– volume: 103
  start-page: 39
  year: 2014
  ident: 2107_CR10
  publication-title: Antivir Res
  doi: 10.1016/j.antiviral.2013.12.009
– volume: 18
  start-page: 2174
  year: 2020
  ident: 2107_CR8
  publication-title: Comput Struct Biotechnol J
  doi: 10.1016/j.csbj.2020.08.006
– volume: 89
  start-page: 8416
  issue: 16
  year: 2015
  ident: 2107_CR22
  publication-title: J Virol
  doi: 10.1128/JVI.00948-15
– volume: 88
  start-page: 2775
  issue: 5
  year: 2014
  ident: 2107_CR23
  publication-title: J Virol
  doi: 10.1128/JVI.03300-13
– volume: 6
  start-page: 2991
  issue: 8
  year: 2014
  ident: 2107_CR13
  publication-title: Viruses.
  doi: 10.3390/v6082991
– volume: 10
  start-page: 9
  issue: 1
  year: 2009
  ident: 2107_CR17
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2609
– volume: 6
  start-page: 863
  issue: 7
  year: 2007
  ident: 2107_CR15
  publication-title: Cell Cycle
  doi: 10.4161/cc.6.7.4032
– volume: 6
  start-page: 2274
  issue: 9
  year: 2014
  ident: 2107_CR20
  publication-title: Genome Biol Evol
  doi: 10.1093/gbe/evu187
– ident: 2107_CR14
  doi: 10.1007/s00203-020-01998-6
– volume: 88
  start-page: 1421
  issue: 3
  year: 2014
  ident: 2107_CR24
  publication-title: J Virol
  doi: 10.1128/JVI.03017-13
– volume: 25
  start-page: 147
  issue: 3
  year: 2000
  ident: 2107_CR28
  publication-title: Trends Biochem Sci
  doi: 10.1016/S0968-0004(99)01540-6
– volume: 31
  start-page: 3784
  issue: 13
  year: 2003
  ident: 2107_CR27
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkg563
– volume: 45
  start-page: D313
  issue: D1
  year: 2017
  ident: 2107_CR30
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw1132
– ident: 2107_CR11
  doi: 10.1101/2020.01.24.919183
– volume: 94
  start-page: e01925
  issue: 4
  year: 2020
  ident: 2107_CR12
  publication-title: J Virol
  doi: 10.1128/JVI.01925-19
– ident: 2107_CR3
  doi: 10.1101/2020.01.23.20018549
– volume: 8
  start-page: 15092.10
  year: 2017
  ident: 2107_CR26
  publication-title: Nat Commun
– ident: 2107_CR5
  doi: 10.1101/2020.01.28.922922
– volume: 92
  start-page: 418
  issue: 4
  year: 2020
  ident: 2107_CR9
  publication-title: J Med Virol
  doi: 10.1002/jmv.25681
– ident: 2107_CR1
SSID ssj0017837
Score 2.5411308
Snippet A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute...
Background A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe...
Abstract Background A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world....
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 58
SubjectTerms Amino Acid Sequence
Amino acids
Biological properties
Cell cycle
Coils
Coronaviridae
Coronaviruses
COVID-19
COVID-19 - genetics
COVID-19 - immunology
COVID-19 - virology
Epidemics
Flow cytometry
Functional analysis
Genome, Viral - genetics
Genomes
HCT116 Cells
Heat resistance
Humans
Hydrophobicity
Identification and classification
Kinases
Localization
Mass spectrometry
Mass spectroscopy
Middle East respiratory syndrome
Molecular Sequence Data
N protein
Nucleic acids
Nucleocapsid protein (N protein)
Nucleocapsid Proteins - chemistry
Nucleocapsid Proteins - genetics
Nucleocapsid Proteins - metabolism
Nucleocapsids
Phosphorylation
Physicochemical properties
Physiological aspects
Protein kinase
Protein structure
Proteins
Random coil
Reproducibility of Results
S phase
SARS-COV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - metabolism
SARS-CoV-2 - pathogenicity
Severe acute respiratory syndrome coronavirus 2
Structure
Target recognition
Tertiary structure
Therapeutic targets
Vaccines
Viral diseases
Viral proteins
Viral Vaccines - therapeutic use
Viruses
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SKPgi2vqxWmUVwQcJ3U2ySfbxLJYqVKFnpW8hySa2ILni3T343zuzyR23CPbFh33YnVl2M5lkZpLJbwh5y6PotXCBdiI2VESrqHPeU-uFAndCSTEuXZx_kWeX4vNVd7VT6gtzwjI8cBbcsY5SCQhiGq-5sMH3zMPgZgPTfmgGNp4jB5u3CabK_oGCuGtzREbL4yXMwhKTbVu8cGVuYoZGtP6_5-QdozRNmNyxQKcPyYPiOtaz_MuPyL2QDsh-Lib5-5Cc5zO3sSzC1TYNNVqtvNgHtxl9pF7EGpy-ej67mNOTr98pqxNiGoNNuwXNrEfghpv0mFyefvx2ckZLsQTqISZYUQ2uk-wsBCiWa8GjE0MTWPSqFUE76WWnwB62tucuxF5GHnlomkG5znEZwFF5QvbSIoVnpLYsNljAyLqB48aotm200NOOQ3_yYCvSbmRnfEESx4IWP80YUWhpsrwNyNqM8ja8Iu-379xmHI1_cn_ALtlyIgb2-AA0wxTNMHdpRkXeYIcaRLlImEbzw66XS_NpfmFmsuOyQ9eoIu8KU1xAG7wtpxJAEgiMNeE8mnDCMPRT8kZvTJkGlgb8S4RoaziQX2_J-CamtqWwWAMPQjZ2EOjoijzNarZtN-dYzkACRU0UcCKYKSXdXI8g4Ur3Gj7-_H9I8gW5z_LYoYwdkb3Vr3V4Cb7Yyr0ah90fwUAtWA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96Ivgifls9pYrgg4RrkzRJn2Q9PE7hFG492beQpMndgbTrdffB_96ZNluvCPewD7uZsu3MZL46-Q0h73gUtRYu0ErEgopoFXXOe2q9UBBOKCmG0sXJN3l8Jr6uqlUquPWprXJnEwdD3XQea-QH4KoR7arg_OP6N8WpUfh2NY3QuE3uIHQZarVaTQlXqSD72h2U0fKgB1ssseW2xA_W52bOaMDs_98yX3NN87bJa37o6AG5nwLIfDFK_CG5FdpH5O44UvLPY3IynryNqRSX27bJ0XeNJT_4OmKQ5F3MIfTLl4vTJT38_pOyvEVkY_Bsa9DPfIBvuGyfkLOjzz8Oj2kamUA9ZAYbqiGAkpWFNMVyLXh0oikCi16VImgnvawUeMXS1tyFWMvIIw9F0ShXOS4DhCtPyV7bteE5yS2LBY4xsq7h-HpU2zJakLfjIFUebEbKHe-MT3jiONbilxnyCi3NyG8DvDYDvw3PyIfpmvWIpnEj9ScUyUSJSNjDD93VuUkby-golYAkt_CaCxt8zTwYf9Yw7ZuiYSojb1GgBrEuWmymObfbvjdflqdmISsuKwyQMvI-EcUOnsHbdDYBOIHwWDPK_RklbEY_X97pjUnGoDf_VDcjb6ZlvBIb3NrQbYEGgRsrSHd0Rp6NajY9N-c41EDCipop4Iwx85X28mKACle61vDnL26-rZfkHht3BWVsn-xtrrbhFcRaG_d62FB_AUDiJVI
  priority: 102
  providerName: ProQuest
Title Identification and functional analysis of the SARS-COV-2 nucleocapsid protein
URI https://www.ncbi.nlm.nih.gov/pubmed/33618668
https://www.proquest.com/docview/2502612033
https://www.proquest.com/docview/2492658828
https://pubmed.ncbi.nlm.nih.gov/PMC7898026
https://doaj.org/article/8f6745490c834aec92c1462d28cd0d27
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEB_uA-VexG-r51JF8EGqbZMm2QeR3eOOU9hTdl1ZfAlpmpwHR_fcD_D-e2f6sW7x8MGHFtpMKJnMdD6S_AbgFfO8r3juooz7OOLeyCjPrY2M5RLdCSl4lboYnYnTKf80y2Y70JY7ahi4vDG0o3pS08Xl218_rz-gwr-vFF6Jd0v8xwraSpvQRXm3XdhHyySposGI_1lVkBiNtQdnbux3ALcZIwR5Ql7dslMVnP_fP-0tq9XdUbllok7uwp3GtwwHtTDcgx1X3odbdbXJ6wcwqg_l-iZLF5qyCMms1dlAfKzhScK5D9ErDCeD8SQ6-vwtSsOSQI_R6F2h6IYVssNF-RCmJ8dfj06jpppCZDFoWEUKfSuRGYxgDFOc-ZwXsUu9lQl3KhdWZBINZmL6LHe-LzzzzMVxIfMsZ8KhJ_MI9sp56Z5AaFIfU4UjkxeMVk6VSbxBUcgZTjhzJoCk5Z22DdQ4Vby41FXIoYSuWa-R7bpivWYBvNn0uaqBNv5JPaQp2VASSHb1Yr44143OaeWF5Bj_xlYxbpztpxbtQlqkyhZxkcoAXtKEaoLBKGmfzblZL5f642SsByJjIiPfKYDXDZGf4xisaY4tICcIOatDedihRD213eZWbnQr5hodUMJwixk2v9g0U0_a-1a6-RppCNMxw0hIBfC4FrPNuFtpDUB2BLDDmG5LefGjQhGXqq_w40__u-czOEhr3YnS9BD2Vou1e44e2irvwa6cyR7sD4_Pvox7VZ6jV6ki3sfD778BFuI6fw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGEIIXxDeBAQGBeEDWEtux3QeEymBq2TqkdUN9M45jj0koKWsrtH-Kv5G7fJRFSHvbQx9aX9rmfOffnXP-HSGveRADLXJPMxESKoJVNM-do9YJBeGEkqLeupgcyNGx-DLLZhvkT3cWBssquzWxXqiLyuEe-TZANbJdJZx_mP-i2DUKn652LTQas9jz578hZVu8H3-C-X3D2O7no50RbbsKUAfB85JqiDFkZiGSt1wLHnJRJJ4Fp1LhdS6dzBQAR2oHPPdhIAMP3CdJofIs59IDosP3XiPXAXgTTPbUbJ3gpQqyve5gjpbbC1j7JZb4pvjC_cAe-NU9Av5HggtQ2C_TvIB7u3fI7TZgjYeNhd0lG768R240LSzP75NJc9I3tFt_sS2LGLGy2WKEtw3nSVyFGELNeDo8nNKdr98oi0tkUgYknYM_xDVdxGn5gBxfiTIfks2yKv1jElsWEmybZPOC4-NYbdNgwb5yDlbEvY1I2unOuJa_HNto_DR1HqOlafRtQNem1rfhEXm3vmbesHdcKv0Rp2Qticzb9QfV2YlpHdnoIJWApDpxmgvr3YA5ABtWMO2KpGAqIq9wQg1ya5RYvHNiV4uFGU8PzVBmXGYYkEXkbSsUKrgHZ9uzEKAJpOPqSW71JMH5XX-4sxvTLj4L889VIvJyPYxXYkFd6asVyCBRZAbplY7Io8bM1vfNOTZRkDCiegbYU0x_pDz9UVOTKz3Q8ONPLv9bL8jN0dFk3-yPD_aeklus8RDK2BbZXJ6t_DOI85b589q5YvL9qr35L-atYns
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+and+functional+analysis+of+the+SARS-COV-2+nucleocapsid+protein&rft.jtitle=BMC+microbiology&rft.au=Gao%2C+Tianyi&rft.au=Gao%2C+Yingdong&rft.au=Liu%2C+Xiangxiang&rft.au=Nie%2C+Zhenlin&rft.date=2021-02-22&rft.pub=BioMed+Central&rft.eissn=1471-2180&rft.volume=21&rft_id=info:doi/10.1186%2Fs12866-021-02107-3&rft_id=info%3Apmid%2F33618668&rft.externalDocID=PMC7898026
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2180&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2180&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2180&client=summon